Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975553 | 0.79 | INPP5A (0.45) | INPP5A | |
| SCHEMBL30161932 | 0.75 | PTGS1 (0.35) | — | |
| SCHEMBL28099163 | 0.70 | INPP5A (0.58) | INPP5A | |
| SCHEMBL26477488 | 0.68 | — | — | |
| SCHEMBL10506390 | 0.68 | INPP5A (0.50) | INPP5A | |
| SCHEMBL14689953 | 0.67 | — | — | |
| SCHEMBL7733581 | 0.67 | INPP5A (0.48) | INPP5A | |
| SCHEMBL28755819 | 0.64 | INPP5A (0.45) | INPP5A | |
| SCHEMBL9685994 | 0.63 | FUCA1 (0.30) | — | |
| SCHEMBL9099973 | 0.63 | INPP5A (0.62) | INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057059-B2 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH | 2005-06-30 | — | — | US | disclosed |
| EP-1517911-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | Faustus Forschungs Cie. Translational Cancer Research GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106469-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | OXGR1, OAT, OXA1L | INPP5A 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.